Doxy-PEP Explained: A Morning-After Pill for Bacterial STIs

Taking a single dose of the antibiotic doxycycline within 72 hours after condomless sex can reduce the risk of chlamydia and syphilis by around two thirds. That is the core finding of several large studies behind doxy-PEP, a prevention strategy that is now part of official guidance in the United States and France, and under active review in the Netherlands. For gay and bisexual men with repeated bacterial STIs, it could change how sexual health care looks in the coming years.

This article explains what doxy-PEP is, what the evidence shows, what experts warn about, and where Dutch policy currently stands.

What is doxy-PEP?

PEP stands for post-exposure prophylaxis. The idea is simple: take medication shortly after a possible exposure to lower the chance of infection. Many readers will know PEP from HIV care, where a 28-day course of antiretrovirals is used after a high-risk contact.

Doxy-PEP works the same way, but for bacterial STIs. The standard dose is 200 mg of doxycycline, taken once, within 72 hours after condomless sex. Doxycycline is a common antibiotic, used for decades against acne, Lyme disease and chlamydia. It is cheap and widely available.

Doxy-PEP targets three infections: chlamydia, syphilis and, to a lesser extent, gonorrhoea. It does not protect against HIV, hepatitis C or viral infections like herpes or mpox. For HIV prevention, PrEP and ongoing vaccine research remain the main tools.

What does the research show?

The most important study is the DoxyPEP trial, published in the New England Journal of Medicine in April 2023. Researchers in San Francisco and Seattle followed more than 500 gay and bisexual men and transgender women, all living with HIV or using HIV-PrEP.

The results were clear:

• Chlamydia cases dropped by about 88 percent.
• Syphilis cases dropped by about 87 percent.
• Gonorrhoea cases dropped by around 55 percent.

A French study, the DOXYVAC trial, found similar effects for chlamydia and syphilis. The protection against gonorrhoea was weaker, because many gonorrhoea strains in Europe are already resistant to tetracycline antibiotics like doxycycline.

Importantly, the same studies found no clear benefit in heterosexual women. A trial in Kenya, published in 2023, showed no significant reduction in STIs. Researchers are still investigating why, but lower adherence and biological differences may play a role.

Why is this relevant now?

Bacterial STIs are rising fast in the Netherlands and across Europe. According to RIVM figures from 2024, syphilis diagnoses among men who have sex with men reached their highest level in over a decade. Chlamydia and gonorrhoea also continue to climb at sexual health clinics (Centra Seksuele Gezondheid).

For some men, especially those on HIV-PrEP, STIs become a recurring issue. Repeated antibiotic courses, repeated clinic visits and the anxiety around results all take a toll. Doxy-PEP offers a way to lower that burden.

In October 2024, the US Centers for Disease Control and Prevention (CDC) released the first national doxy-PEP guideline. It recommends offering doxy-PEP to gay and bisexual men and transgender women who have had a bacterial STI in the past year. France issued a similar recommendation in 2024 through its national health authority, the Haute Autorité de Santé.

What about the Netherlands?

Dutch policy is more cautious. The professional association NVHB (Nederlandse Vereniging van HIV Behandelaren) and the Soa AIDS Nederland foundation published a joint statement in 2024. They acknowledge the evidence but do not yet recommend general use.

Several Dutch HIV clinics already prescribe doxy-PEP off-label to selected patients. This is usually men with frequent syphilis or chlamydia infections, after a conversation with their HIV consultant or sexual health doctor. A formal national guideline is expected, but no date has been set.

The Aidsfonds has called for faster decision-making, arguing that the evidence is strong enough to act. Critics, including some microbiologists, want more time to study the risks.

The big concern: antibiotic resistance

The main worry is not the safety of doxycycline for the individual. The drug is well-tolerated, with mild side effects like stomach upset and sun sensitivity. The concern is at the population level: regular antibiotic use can drive antimicrobial resistance.

Two questions matter most:

1. Will gonorrhoea become harder to treat? Gonorrhoea already shows resistance to many antibiotics. Wider doxycycline use could speed this up.
2. What happens to other bacteria in the body? Doxycycline also affects gut bacteria and common skin bugs like Staphylococcus aureus. Long-term effects are not fully known.

A follow-up analysis of the DoxyPEP trial found a modest rise in doxycycline-resistant S. aureus in users. The clinical meaning of this finding is still debated. The WHO has urged countries to monitor resistance closely if they introduce doxy-PEP.

Who might benefit, and who probably not?

Based on current guidance from the CDC and French authorities, doxy-PEP is most useful for:

• Gay and bisexual men with one or more bacterial STIs in the past year.
• Transgender women in the same situation.
• People on HIV-PrEP or living with HIV who keep getting reinfected.

It is generally not advised for:

• People with rare or no STI exposures, where the trade-off with resistance is unfavourable.
• Cisgender heterosexual women, based on current trial data.
• Pregnant people, because doxycycline can affect fetal bone and teeth development.

What should you do as a reader?

Doxy-PEP is not a do-it-yourself project. Buying doxycycline online without medical follow-up means no testing, no resistance monitoring and no proper STI care. That undermines both your own health and public health.

If you think doxy-PEP could be relevant for you, the practical steps are:

• Talk to your GP, HIV consultant or the doctor at your local Centrum Seksuele Gezondheid.
• Get a full STI check, including HIV and syphilis blood tests.
• Discuss how often you have condomless sex and how many STIs you have had recently.
• Agree on regular testing if you start doxy-PEP — usually every three months.

Doxy-PEP is not a replacement for condoms, vaccination against hepatitis A, B and HPV, or regular testing. It is an extra tool. Used wisely, it can lower infections sharply. Used carelessly, it could make some infections harder to treat for everyone.

The coming year will likely bring a formal Dutch guideline. Until then, the message from experts is consistent: the science is promising, the conversation belongs in the doctor's office, and resistance monitoring is essential.